Results 281 to 290 of about 307,887 (342)

The association between the quality and quantity of carbohydrate intake and the size, depth, and Wagner grade of diabetic foot ulcers in patients with type 2 diabetes. [PDF]

PLoS One
Geravand F, Nasli-Esfahani E, Montazer M, Jalalzadeh M, Azadbakht L.   +4 more
europepmc   +1 more source

Comparison of the Effects on Glycemic Control and Taste Between Newly Invented "Japanese Diet Sweets" and "Conventional Japanese Sweets".

, 2000
Seiko Itagaki, Toru Kinoshita, Setsuko Hirao, Koichi Hirao   +3 more
openalex   +2 more sources

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source

Dietary glycemic index, glycemic load, and risk of COVID-19: a prospective cohort study. [PDF]

J Health Popul Nutr
Shamshirgardi E, Masoumi SJ, Kazemi A, Nouri M, Shahsavani Z, Clark CCT, Behzadi M, Akbarzadeh M.   +7 more
europepmc   +1 more source

Centrally-acting antihyper-glycemic action of orexin-A and -B in streptozotocin-diabetic mice

, 2000
Ritsu Honda, Y. SUGIHARA, Ikuko Kimura
openalex   +1 more source

Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT‐2 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim To assess the efficacy and safety of once‐weekly tirzepatide in Japanese participants with obesity and type 2 diabetes (T2D). Materials and Methods This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT‐2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle ...
Toshimasa Yamauchi, Taro Asakura, Tomotaka Shingaki, Tomonori Oura, Hideki Katagiri   +4 more
wiley   +1 more source

A global call to action: strengthening strategies to combat dysglycemia and improve public health outcomes. [PDF]

Front Public Health
Hirani K, Sundheim B, Blaschke M, Lemos JRN, Mittal R.   +4 more
europepmc   +1 more source

Improvement in patient-reported sleep in type 2 diabetes and prediabetes participants receiving a continuous care intervention with nutritional ketosis [PDF]

, 2019
Athinarayanan, Shaminie, Bhanpuri, Nasir H, Campbell, Wayne W, Hallberg, Sarah J, McCarter, James P, McKenzie, Amy L, Phinney, Stephen D, Siegmann, Morgan J, Van Dort, Christa J, Volek, Jeff S   +9 more
core   +1 more source

Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are available in two fixed‐ratio combinations (FRCs) for the treatment of type 2 diabetes (T2D), insulin degludec with liraglutide and insulin glargine with lixisenatide.
Kevin Cowart, Nicholas W. Carris
wiley   +1 more source